Exhibit 99.1 Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, MD – May 9, 2024 – Altimmune, Inc. (Nasdaq: ALT), a clinical- stage biopharmaceutical company, to ...

GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/inv ...

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences: BTIG Obesity Health Forum (Virtual Conference) Title: Emerging Therapeutics Panel Wednesday, May 8, 2024 Panel Discussion at 4:00 pm Eastern Time GLP-1-Based Therapeutics Summit (Philadelphia, PA) Title: Focusing on the Use of GLP ...

Altimmune团队对Stephen Harrison博士的悼念 - Altimmune团队对Stephen Harrison博士的意外离世表示悲痛和诚挚的哀悼[1] - Altimmune团队将怀念他，并感谢曾经与他相识和合作的机会[3] Harrison博士的贡献 - Harrison博士在代谢性肝病治疗方面的贡献将在我们领域留下深远而持久的影响[2]

Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment. The active ingredients produce substantially greater weight loss than any other drugs on the market. I’d venture a guess that some investors assume that the best returns have already been had. However, there’s lots of evidence suggesting otherwise. Global obesity spending is ...

Key Points Wegovy patients lost an average of 16% of their body weight against 2% for placebo users in clinical trials. Zepbound patients lost 20.9% body weight and up to 26% after 88 weeks compared to 9.5% for the placebo group, but dosages rose to 15 mg a week versus 2.4 mg for Wegovy. Both drugs are being researched for additional indications, including cardiovascular, MASH and neurological diseases. 5 stocks we like better than Novo Nordisk A/S The GLP-1 weight loss trend continues to flourish, and the ...

公司背景 - Altimmune是一家专注于肥胖和肝病治疗的临床阶段生物制药公司[2] 产品研发 - 公司的主要产品是Pemvidutide（ALT-801），针对肥胖和MASH进行研发[3] - Pemvidutide通过激活GLP-1和胰高血糖素受体实现减重效果，同时减少胃肠道副作用和心脏事件[4]

生物技术股票市场 - 生物技术股票市场提供了一些最具爆炸性和令人兴奋的机会[1] - Viking Therapeutics (NASDAQ:VKTX)是一个很好的例子，其在体重减轻药物方面取得了成功，股价从11月的每股约10美元飙升到99.41美元[2] - Altimmune (ALT)是另一家热门生物技术股票，其股价从11月的每股约2.34美元飙升到14.84美元[6] - Fortress Biotech (NASDAQ:FBIO)是一家具有重大催化剂的生物技术便士股票，分析师们对其股价目标进行了调高[9] - Silence Therapeutics (NASDAQ:SLN)利用RNA干扰机制来抑制特定靶基因的表达，其SLN-360和diversiran治疗方案取得了成功[15]

生物技术行业增长因素 - 新创新、数百万即将退休的婴儿潮一代、对更好医疗的需求、制药公司专利即将到期、并购复苏、新的治疗方法推动了生物技术行业的增长[2] 股价上涨原因 - Eli Lilly和Novo Nordisk等公司的股价上涨部分原因是由于肥胖药物销售的增长，以及在药物试验中取得积极结果[3]

公司概况 - Altimmune, Inc. 是一家专注于治疗肥胖和肝病的临床阶段生物制药公司[332] 业务更新 - 2023财年业务更新包括FDA授予pemvidutide治疗MASH的快速通道指定[333] - 2023年11月30日，Altimmune宣布了pemvidutide肥胖试验48周的顶线结果[335] 费用情况 - 研发费用主要包括与CRO和临床试验相关的费用，员工相关费用，以及与临床活动和监管操作相关的成本[341] - pemvidutide的研发费用减少主要是由于与MASLD试验相关的费用减少[347] 财务状况 - 2023年营收为426,000美元，较2022年增长726%[346] - 总其他收入（费用）净额在2023年比2022年增加了4652万美元，主要是由于利息收入和外汇汇率变动的增加[351] - 截至2023年12月31日，公司现金、现金等价物、受限现金和短期投资总额为1.979亿美元[doc id='353'] - 在2023年，公司通过股权交易、货币市场基金和短期投资的利息和股息以及短期投资到期所得到的现金是主要来源[doc id='353'] - 在2023年，公司通过股权分销协议获得了约8,660万美元的净收益[doc id='356']